Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.36 USD | -0.78% | +9.51% | +340.28% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 188M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.04
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
1 day | +0.31% | ||
1 week | +15.70% | ||
Current month | +305.70% | ||
1 month | +305.70% | ||
3 months | +421.14% | ||
6 months | +612.38% | ||
Current year | +336.05% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 6.428 | +0.29% | 31 025 |
24-04-29 | 6.41 | +0.31% | 366,194 |
24-04-26 | 6.39 | -0.62% | 391,978 |
24-04-25 | 6.43 | +6.28% | 750,648 |
24-04-24 | 6.05 | +2.37% | 672,175 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+336.05% | 188M | |
+1.77% | 42.86B | |
+45.26% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- CADL Stock